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ABSTRACT 
 
Herein we review the various methods currently in use for 
determining the expression of chemokines by CNS cells in 
vitro. Chemokine detection assays are used in conjuction with 
one another to provide a comprehensive, biologically relevant 
assessment of the chemokines which is necessary for correct 
data interpretation of a specific observed biological effect. The 
methods described include bioassays for soluble chemokine 
receptors, RNA extraction, RT-PCR, Real - time quantitative 
PCR, gene array analysis, northern blot analysis, Ribonuclease 
Protection assay, Flow cytometry, ELISPOT, western blot 
analysis, and ELISA. No single method of analysis meets the 
criteria for a comprehensive, biologically relevant assessment 
of the chemokines, therefore more than one assay might be 
necessary for correct data interpretation, a choice that is based 
on development of a scientific rationale for the method with 
emphasis on the reliability and relevance of the method. 
 
INTRODUCTION 
 
Chemokines, also known as chemotaxic cytokines, are secreted 
proteins that function as chemoattractants, mediating the 
recruitment of various subsets of leukocytes to sites of tissue 
damage to mediate specific immunological functions (1, 2). 
Chemokines were first discovered in 1987. They play a role in 
activating the immune system’s response to infection. These 
signaling molecules attach themselves to specific binding sites 
(receptors) on immune cells, trigger the cells to respond to 
infection, and call more immune cells to infected areas to fight 
invading microbes. The chemokine molecules share structural 
similarities, including four conserved cysteine residues which 
form disulphide bonds in the tertiary structure of the proteins. 
Traditionally, the chemokine superfamily has been divided into 
two subgroups: C-X-C (where X is any amino acid) and C-C, 
according to whether an intervening residue occurs between the 
two cysteines. This structural distinction has been shown to 
delineate a general, though not absolute, distinction in the 
biological properties of these molecules. Most C-X-C 
chemokines are chemoattractants for neutrophils (and to some 
extent lymphocytes) but not monocytes, whereas C-C 
chemokines appear to attract monocytes, basophils, 
eosinophils, and lymphocytes (including NK cells) but not 
neutrophils. A third “C” branch of these molecules are called 
lymphotactin. The representative of these C chemokines is a 
chemoattractant for lymphocytes and NK cells, but it does not 
attract either monocytes or neutrophils. 
 
Chemokines mediate their activities by binding to target cell 
surface chemokine receptors that belong to the large family of 
G protein-coupled, seven transmembrane (7 TM) domain 
receptors (also called serpentine receptors) (3). Based on the 
receptor nomenclature established at the 1996 Gordon 
Research Conference on chemotactic cytokines, the chemokine 
receptors that bind CXC chemokines are designated CXCRs 
and the receptors that bind CC chemokines are designated 
CCRs. Leukocytes have generally been found to express more 
than one receptor type. The various CXCRs and CCRs are 
known to exhibit overlapping ligand specificities. It was only 
in 1995, however, that the connection between chemokines and 
HIV infection became clear. Cytotoxic T lymphocytes (CTLs) 
secrete certain chemokines that can suppress HIV activity. 
Three specific chemokines—RANTES, MIP1α, and MIP1β—
were found to work together to block HIV replication. 
Suppressive factors, secreted by CTLs may also be involved in 
HIV suppression. AIDS researchers have shown that a specific 
receptor molecule called CD4, on the surface of immune cells 
which allows HIV to enter cells however the CD4 alone was 
not sufficient for HIV to infect the immune cells. A second 
receptor needed for the entry of HIV into cells was identified 
and named “fusin” (CXCR4) because it enables certain strains Mahajan et al.    
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of HIV to fuse with and enter immune cells called T cells. An 
analysis of the structure of fusin revealed that it was a receptor 
for chemokines, the family of signaling molecules that includes 
beta-chemokines, which were shown to suppress HIV activity 
(4). Yet another chemokine receptor, called CCR5, was 
necessary for the entry of HIV into immune cells called 
macrophages. This receptor was already known to be the 
binding site for the chemokines recently found to play a pivotal 
role in suppressing HIV infection. The new findings suggest 
that the three chemokines suppress HIV replication by binding 
to the same receptors needed by certain strains of HIV to enter 
immune cells. It might be possible to treat HIV infection by 
developing drugs that block the coreceptors needed for HIV 
entry. Vaccines that trigger the activity of immune cells that 
inhibit the binding of HIV to coreceptors may be able to 
prevent infection. Although still in its early stages, the 
development of therapies and vaccines based on chemokine 
receptors promises to strengthen a growing arsenal of weapons 
for use in fighting HIV. 
 
Expression of a variety of chemokines and receptors was 
shown to be increased in HIV encephalitis brain tissues 
particularly in areas of neuroglial reaction (4). Presence of 
chemokine receptors on neurons may be involved in the 
pathogenesis of neurologic damage in AIDS patients. 
Macrophages are potential carriers of latent HIV-1 and on 
activation may be implicated in spreading the infection to other 
neighbouring cells, such as microglia or astrocyte. Microglia, 
resident macrophages of the CNS, may contribute to this 
process by elaborating chemoattractants that are capable of 
recruiting leukocytes across the blood-brain barrier. HIV 
infection of macrophages and subsequently astrocytic cells can 
contribute to the establishment of a chronic inflammatory state 
in the CNS, eventually resulting in HIV encephalitis, by 
increasing the secretion of pro-inflammatory cytokines. A 
great deal of attention has recently been focused on the 
regulation of chemokine expression and function following 
exposure to opioids, cannabinoids, or cocaine (5, 6, 7). It is not 
surprising that these drugs would be found to alter chemokine 
expression, since there is a rather extensive literature base 
showing that drugs of abuse can modulate the production of 
other cytokines. Certain drugs of abuse can alter the expression 
and/or function of the chemokine receptors (7). For example, 
pre-treatment with opioids leads to an inhibition of chemotaxis 
of neutrophils, monocytes, and dendritic cells to either 
complement-derived chemotactic factors or the chemokines 
MIP-1β, RANTES, MCP-1 and IL-8. 
 
The levels of the chemokines in body fluids / tissues or culture 
supernatants can be measured by a broad variety of assays (8) 
as shown in the Table 1. 
 
 
 
Table 1: 
Measurement of chemokines in culture supernatants and 
serum 
•  ELISA / Colorimetric methods / bioassays for soluble 
receptor levels (9, 22, 23) 
Chemokine production by different populations of immune 
cells 
•  Flow cytometric Analysis (19) 
Differential Gene Expression technologies for transcripts 
for chemokines /chemokine receptors, Chemokine gene 
profiling 
•  mRNA based assays – including RT-PCR / Real time 
Quantitative-PCR / Nothern Blot analysis / Rnase 
Protection assays (RPA), Gene array analysis (11, 12, 15, 
16, 17, 18, 21) 
Single cell assays for chemokine secretion 
•  ELISPOT (24) 
 
We investigated the in-vitro effects of various drugs of abuse 
on gene expression and production of the various β 
chemokines, MCP-1, MIP−1β respectively and their specific 
receptors, CCR2b (MCP-1), CCR3 (MIP-1β ), and CCR5 
(MIP-1 α & β) on the neuronal cell lines, U373 and U87. We 
have outlined below a brief summary of each of the methods 
used in our laboratory for chemokine detection, however we 
have only provided results using a couple of the mentioned 
techniques to illustrate how the chemokine detection assay are 
used in conjuction with one another to provide a 
comprehensive, biologically relevant assessment of the 
chemokines which is necessary for correct data interpretation 
of a specific observed biological effect. 
 
MATERIALS AND METHODS 
 
Cell culture 
 
Neuronal cell lines U373 (ATCC HTB) and U87(ATCC 
HTB-14) were obtained from the American Tissue Culture 
Collection(ATCC). Both cell lines cells are derived from a 
human malignant glioma / grade III tumor. Cultures are 
maintained in complete medium [Eagles MEM with non-
essential amino acids, sodium pyruvate 1mM and Earl’s 
BSS 90% and 10% Fetal bovine serum]. U373 and U87 
cells (3.2 X 10
-6 / 60 mm dish) were cultured with drugs of 
abuse like morphine at concentrations ranging from 10
-7 to 
10
-15 M for 24 to 96 hr at 37˚C in a 5% CO2 incubator. 
Supernates were harvested and stored at -70˚C
  and 
chemokines quantitated by ELISA, RNA was extracted 
from the cells for RT-PCR, real time quantitative PCR and 
northern blot analysis.  
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Bioassays for soluble chemokine receptors 
 
Biological activity of chemokine receptors is determined in 
cellular assays, where the chemokines receptors are available 
as soluble proteins. Chemotaxis in leukocytes is mediated 
through binding of soluble chemokines to transmembrane G-
protein coupled receptors. Chemokines selectively recruit and 
activate a variety of cells during inflammation. Interactions 
between cell surface glycosaminoglycans (GAGs) and 
chemokines drive the formation of immobilized gradients of 
chemokines at the site of inflammation, directing this 
recruitment. Chemokines can therefore form complexes with 
both cell surface and soluble GAGs. Soluble GAG chemokines 
complexes are unable to bind the receptor, thus, resulting in a 
block of the biological activity.Soluble chemokine receptors 
can be found in the blood and extracellular fluid. These soluble 
receptors result from enzymatic cleavage of the extracellular 
domain of cell-bound chemokine receptors. The released 
soluble fragments can bind chemokine molecules, thereby 
neutralizing their activity (9). Bioassays are divided into four 
broad categories based on the type of function measured in the 
target cells incubated in the presence of a chemokine: a) assays 
which measure proliferation, b) assays of cytotoxicity, c) 
assays dependent on the induction of a specific cell function 
such as chemotaxis, and d) assays estimating the quantity of a 
protein induced in a target cell. Bioassays for chemokine 
receptors are sensitive in the pictogram range, but are not 
specific, and neutralizing with a chemokine specific antibody 
is necessary to confirm the identity of the measured chemokine 
receptor. This is because several different chemokines in the 
unknown sample could mediate the same biological activity. 
Bioassays are more time consuming and laborious than 
immunoassays. They require target cell line which is 
modulated by the biological response being measured. 
Bioassays are mainly used for validation purposes rather than 
routine chemokine measurements. Bioassays are more often 
used for confirmation and validation of the results obtained by 
other chemokine detection methods. Bioassays are infrequently 
performed, because they are labor intensive, analysis of the 
dose response curves generated in the bioassays requires 
extensive curvefitting statistics based computer analysis, and 
they are not appropriate for large scale screening and rapid 
throughput. 
 
RNA extraction 
 
Cytoplasmic RNA was extracted by an acid guanidinium-
thiocyanate-phenol-chloroform method as described (10, 11).  
 
Gene Array Analysis 
 
Gene arrays are solid supports upon which a collection 
(oligonucleotides numbers ranging from 20-1000) of gene-
specific nucleic acids have been placed at defined locations, by 
spotting onto a membrane. In array analysis, a nucleic acid 
containing sample is labeled and then allowed to hybridize 
with the gene-specific targets on the array. The nucleic acids 
attached to arrays are called “targets,” whereas the labeled 
nucleic acids comprising the sample are called “probes.” Based 
on the amount of probe hybridized to each target spot, 
information is gained about the specific nucleic acid 
composition of the sample. The major advantage of gene 
arrays is that they can provide information on thousands of 
targets in a single experiment. Currently the solid supports 
upon which nucleic acids are arrayed are either glass slides or 
nylon membranes. Typically, fluorescently labeled probes are 
used with glass arrays, while radiolabeled probes are used with 
membranes. Depending on the type of array, the arrayed 
nucleic acids may be composed of oligonucleotides, PCR 
products or cDNA vectors or purified inserts. The sequences 
may represent entire genomes and may include both known 
and unknown sequences or may be collections of sequences of 
cytokines. Many pre-made and custom arrays are available 
from commercial manufacturers although many labs prepare 
their own arrays with the help of robotic arrayers. The methods 
of probe labeling, hybridization, and detection depend on the 
solid support to which the sequences are bound. Gene arrays 
may be used for sequence identification (e.g. mutation 
analysis) or differential expression analysis of two or more 
RNA samples. Gene arrays have become a powerful tool for 
comparing complex sample RNA populations. Using array 
analysis, the expression profiles of normal and tumor tissues, 
treated and untreated cell cultures, developmental stages of an 
organism or tissue, and different types of tissues can be 
compared (12). Nylon membrane arrays are typically 
hybridized with 
32P-dNTP labeled probes and analyzed by a 
phosphorimager or autoradiography using appropriate 
densitometric scanning software. A different array must be 
used for each sample analyzed. A typical experiment involves 
isolating RNA from two tissue or cell samples. The RNAs are 
reverse transcribed using labeled nucleotides and target 
specific, oligo dT, or random-sequence primers to create two 
labeled cDNA populations. The two cDNAs are hybridized to 
two identical arrays. After washing, the hybridized signal on 
each array is detected and analyzed. The signal emitting from 
each gene-specific spot is compared between the populations. 
Genes expressed at different levels in two samples generate 
different amounts of labeled cDNA and this results in spots on 
the array with different amounts of signal (13). Differences in 
expression of specific sequences are often validated by another 
method of analysis such as RT-PCR, Northern analysis or 
nuclease protection assays. These same methods can be used 
for relative or absolute quantitation of specific messages of 
interest identified by array analysis.  
 
RT-PCR 
 
Extracted RNA was used for RT-PCR as described by the 
manufacturer employing a Perkin Elmer kit (Cat # N808-
0143). Briefly, RNA was reverse transcribed to make a DNA 
copy for use in PCR (14). One µg of RNA was added to a tube 
containing 5 mM MgCl2, 1 mM of each dNTP (A, T, G, C), 50 Mahajan et al.    
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mM KCl, 10 mM pH 8.3 Tris Buffer, 2.5 uM oligo dT, 20 
units of RNAse-inhibitor and 50 units of MuLV reverse 
transcriptase. The mixture was incubated at 45˚C for 35 min, 
heated to 95˚C for 5 min and placed on ice until used for PCR. 
The newly synthesized cDNA was then amplified by PCR 
using specific sense and antisense primers for the genes of 
interest along with a housekeeping gene, glucose-3-phosphate 
dehydrogenase (G3PDH) or β-actin, as a control. Briefly, to 
each tube, a 10 µl sample of the RT product in a final 
concentration of 2 mM MgCl2, 10 mM Tris pH 8.3, 50 mM 
KCl, plus 0.02 µM of both the 5’ and 3’ primers of the genes 
of interest, and 2.5 units of Taq polymerase were added. The 
mixture was placed in a thermocycler for 30 cycles of 95˚C for 
30 sec, 60˚C for 30 sec and 74˚C for 1 min. The PCR 
conditions were modified slightly for each 
chemokine/chemokine receptor gene to obtain optimal results. 
Samples were separated by 1-1.2% agarose gradient gel 
electrophoresis along with molecular weight markers for 
reference. Resultant bands were visualized with UV light, 
photographed, size determined and optical density (OD) was 
quantified using a scanning densitometer. All values were 
normalized to the constitutive expression of the housekeeping 
gene.  
 
Real Time Quantitative RT-PCR 
 
Relative abundance of each mRNA species was assessed using 
the SYBR green master mix from Stratagene to perform real 
time quantitative PCR (15). The ABI Prism 5700 sequence 
detection system detects and plots this increase in fluorescence
 
versus PCR cycle number to produce a continuous measure of 
PCR
 amplification. To provide precise quantification of initial
 
target in each PCR reaction, the amplification plot is examined
 
at a point during the early log phase of product accumulation.
 
This is accomplished by assigning a fluorescence threshold 
above
  background and determining the time point at which 
each sample’s
 amplification plot reaches the threshold (defined 
as the threshold
 cycle number or CT). Differences in threshold 
cycle number are
 used to quantify the relative amount of PCR 
target contained
 within each tube.
 
 
Calculation of Relative Expression 
 
Relative expression of mRNA species was calculated using the 
comparative
 CT method. All data were controlled
 for quantity 
of RNA input by performing measurements on an endogenous
 
reference gene, β-actin or G3PDH. In addition, results on RNA
 
from treated samples were normalized to results obtained on 
RNA
 from the control, untreated sample. Briefly, the analysis 
was performed as
 follows:
  
 
For each sample, a difference in
  CT values (∆CT) was 
calculated for each mRNA by taking the mean
 CT of duplicate 
tubes and subtracting the mean CT of the duplicate
 tubes for the 
reference RNA (β-actin or G3PDH) measured on an aliquot
 
from the same RT reaction.
  
 
∆CT = CT(test gene) - CT(β-actin)
  
 
The ∆CT for the treated sample was then subtracted from
 the 
∆CT for the untreated, control sample to generate a ∆∆CT.  
 
Thus ∆∆CT = ∆CT(treated sample) - ∆CT( untreated control)
  
 
The mean of these ∆∆CT measurements
  was then used to 
calculate expression of the test gene (2
-∆∆CT) relative
  to the 
reference gene and normalized to the untreated control as 
follows:
  
 
Relative Expression = 2
-∆∆CT  
 
This calculation assumes that all PCR reactions are working
 at 
100% efficiency. All PCR efficiencies were found to be >95%; 
therefore,
  this assumption introduces minimal error into the 
calculations.
  
 
Northern Hybridization 
 
Northern blot analysis was performed as recommended in 
Current Protocols in Molecular Biology (11, 16, 17). Briefly, a 
total of 10-20 µg of denatured RNA was loaded per lane and 
was resolved using a denaturing gel containing formaldehyde 
to obtain good resolution of the denatured RNA and then 
transferred onto a nylon membrane. After crosslinking, the 
membrane is then prehybridized at 68˚C for 1 hr followed by 
hybridization at 68˚C overnight using Ultrahyb (Ambion, 
Austin, TX) mixed with the 
32P labeled specific probe. The 
cDNA probe was generated using the TOPO -TA cloning kit 
from Invitrogen (cat # K4500-01). The cDNA probe was 
labelled using the Random primer labeling method, with P
32 
using a PRIME it- II kit from Stratagene. After hybridization, 
the membrane was washed with low and high stringency 
buffers and the blots were exposed to Biomax-MS film 
(Eastman KODAK, Rochester, NY). The autoradiograph 
obtained was then scanned and bands quantified using a 
densitometer. All results were normalized to the housekeeping 
gene, β-actin. 
 
Ribonuclease protection assay 
 
The ribonuclease protection assay (RPA) is a sensitive method 
used for the detection of low-abundant mRNA in a complex 
mixture of total cellular RNA (18). The RPA is based on 
solution hybridization of a 
32P-labeled riboprobe to target 
mRNA. Radioactive riboprobes have a short useful life and 
disintegrate within 7 days of synthesis. To circumvent the 
problems of using radioactivity, non-radioactive RPA using 
biotinylated riboprobes can be developed.  
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Riboprobe synthesis 
 
Total RNA was isolated from cells with the Trizol reagent 
(Sigma, St. Louis, MO). The cDNA was synthesized in a 25 
µL volume containing 2 µg total RNA, 0.5 µg random 
hexamer, 500 µM dNTPs, 10 mM DTT, 20 U RNase inhibitor 
and 200 U MMLV reverse transcriptase (Promega, Madison, 
WI) at 37˚C for 60 min. The PCR reactions were carried out in 
a 50 µL volume containing 5 µL of the RT product, 2.5 mM 
MgCl2, 200 mM dNTPs, 400 nM of each sense and antisense 
primers, and 2.5 U Taq DNA polymerase (Sigma, St. Louis, 
MO). Riboprobes were synthesized by in vitro transcription 
carried out in a 20 µL volume containing 5 mL of PCR 
products, 20 U RNase inhibitor, 20 units of T7 RNA 
polymerase (Ambion, Austin, TX), 0.5 mM each of ATP, GTP, 
UTP with 0.3 mM CTP and 0.2 mM biotin-labeled-14-CTP 
(Gibco BRL, Grand Island, NE) at 37˚C for 2 h. 
 
Ribonuclease protection assay 
 
Ten µg of total RNA was hybridized with 40 pg of riboprobe 
overnight at 45˚C. Single-stranded RNA was then digested 
with a mixture of 250 U/mL RNase A and 10,000 U/mL 
RNase T1 for 30 min at 37˚C. After inactivation of RNase with 
20 µL of 10% SDS and 0.5 µL of 20 mg/mL proteinase K for 
20 min at 37˚C, protected RNA was extracted with 400 µL of 
phenol / chloroform / isoamylalcohol (25:24:1) and separated 
on a 5% acrylamide/8M urea denaturing gel. The protected 
RNA was electrophoretically transferred (Transblot, BioRad) 
onto a positively-charged nylon membrane (Schleicher & 
Schuell, Germany) with 0.5X TBE at 400 mA for 1 hr. After 
UV-crosslinking, the membrane was exposed to BioMax X-ray 
film (Eastman KODAK, Rochester, NY) overnight. 
Autoradiographs were scanned and images were analyzed 
using densitometric software (Syngene, MD).  
 
FACS analysis 
 
Multicolor immunofluorescent staining was used to identify 
and quantify the number of U373 cells expressing the surface 
chemokine receptor, CCR5, in response to treatment with 
morphine. Approximately 1x10
6 cells were treated with 10
-7 M 
morphine for 24 hr and cells were harvested, trypsinized, 
washed, and suspended in staining buffer. FACS conditions 
were optimized by adjusting the settings for photomultiplier 
tube voltage and compensation using appropriate cell surface 
staining controls and quadrant markers were set using specified 
isotype controls for the flurochrome-conjugated antibody used 
(19). Monoclonal antibodies (mAbs) against CCR5 were 
conjugated to fluroscein isothiocyanate (FITC) and the 
matched isotype control was obtained from BD Biosciences-
Pharmingen (San Diego, CA). For surface marker analysis, Fc 
receptors were pre-blocked by incubating cells with an excess 
of irrelevant purified IgG and then stained with 0.5 µg of 
FITC-conjugated mAb specific for the cell surface antigen, 
CCR5. Cells were washed twice with staining buffer, pelleted 
by centrifugation at 250 x g and the supernatant fluid removed. 
Cells were then washed in PBS and fixed and then resuspended 
in staining buffer prior to flow cytometric analysis using a 
FACS Calibur instrument (BD Biosciences, San Jose, CA). 
Stained cells were subjected to light scatter analysis and a 
fixed population of cells were gated after quandrant markers 
were set, based on the isotype control and represented as FL-1 
(FITC-labeled) on the X axis. Cells positive for CCR5 were 
expressed as a percentage of the total cells gated (20). 
 
Western blot analysis 
 
Western or immunoblotting is a commonly employed 
technique for the detection of protein antigens in complex 
mixtures (21). Cells were lysed and protein extracted using 
Mammalian Protein Extraction Reagent (M-PER
TM) (Pierce 
Inc., Rockford, IL). Samples were then separated by SDS-
polyacrylamide gel electrophoresis. Separated proteins are then 
transferred to a membrane (usually nitrocellulose, polyvinyl 
pyrolidon, or nylon). These membranes are incubated with an 
antibody specific for the protein of interest which binds to the 
protein band immobilized on the membrane. The antibody is 
then visualized with a detection system that is usually based on 
a secondary protein binding to Ig chains which is linked to a 
color-yielding reaction. We believe that the effects of 
morphine on chemokine gene regulation observed may be 
mediated via the µ opioid receptor, therefore we used western 
blot analysis with anti-µ opioid receptor antibody to determine 
if neuronal cells express the µ opioid receptor and if its 
expression can be modulated by morphine. The anti-µ opioid 
receptor antibody (BD Biosciences-Pharmingen, Catalog # 
60751A, Lot # M034672) is an affinity purified, polyclonal 
antibody produced in rabbits against the human µ opioid 
receptor that recognizes both human and rat µ opioid receptors. 
The antibody is used for western blot analysis at a 
concentration of 2 µg/ml and identifies the µ  receptor as a 45 
kD band. U373 and U87 cells and normal human astrocytes 
were cultured with 10
-7 M morphine and washed. Total protein 
was extracted using M-PER
TM, 30 µg of total protein was 
loaded per lane and separated using a 7.5% SDS-Tris glycine 
PAGE gel. Gels were blotted onto nitrocellulose membranes 
(Novex, San Diego, CA) and blocked overnight by incubating 
with 1X TBS containing 0.1% Tween and 5% nonfat dry milk. 
Membranes were probed with the above antibodies against the 
µ opioid receptor. After incubation with the primary antibody, 
the membrane was incubated for 2 hr at room temperature with 
biotin-conjugated, goat anti-rabbit IgG antibody. After 3 
washes of 10 min each, blots were incubated for another 30 
min with a streptavidin-alkaline phosphatase conjugate (Gibco-
Life Technologies, Grand Island, NY) followed by 
colorimetric detection using NBT/BCIP reagent (Roche, 
Indianapolis, IN). 
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ELISA  
 
The ELISA assays employ the quantitative sandwich enzyme 
immunoassay technique (22, 23). A monoclonal antibody 
specific for a particular chemokine is pre-coated onto a 
microplate. Standards and samples are pipetted into the wells 
and the chemokine present in the sample or standard is bound 
by the immobilized antibody. After washing away any 
unbound substances, an enzyme-linked polyclonal antibody 
specific for the chemokine of interest is added to the wells. 
Following a wash to remove any unbound antibody-enzyme 
reagent, a substrate solution is added to the wells and color 
development in proportion to the amount of chemokine bound 
to the plate is measured as optical density based on the color 
intensity using a spectrophotometer at a specific wave length. 
We quantitated chemokine protein secretion in culture 
supernates using commercially available, highly specific and 
sensitive ELISA kits from R&D systems (Minneapolis, MN) 
and Biosource International (Camarillo, CA) according to the 
instructions supplied by the manufacturer. 
 
ELISPOT assay to quantify the secretion of 
cytokines by T lymphocytes 
 
The enzyme-linked immunospot (ELISPOT) assay is a 
powerful tool for detecting and analyzing individual cells that 
secrete a particular protein in vitro (24). Although originally 
developed for analyzing specific antibody-secreting cells, the 
assay has been adapted for measuring the frequency of cells 
that produce and secrete a variety of other molecules such as 
cytokines.
  The protocol involves activation of the T 
lymphocytes (T cells) in vitro with antigen. The wells of the 
ELISPOT plate are coated with antibody specific for the 
assayed cytokine. The antibody binds to the nitrocellulose base 
of the ELISPOT plate. Activated T cells are then transferred to 
the ELISPOT plate, and the cytokines are released during the 
overnight incubation period. Those cytokines that are released 
locally around each T cell bind to and are therefore “captured” 
by the specific antibody. The cells and any excess cytokines 
are washed off. A second antibody that is also specific for the 
cytokine of interest is added; this antibody is coupled to an 
enzyme that is capable of converting a substrate into an 
insoluble colored product. The plates are washed once more, 
and the enzyme substrate is added. The substrate is converted 
into the insoluble product, forming spots of color representing 
areas of captured cytokines that are secreted by adjacent T 
cells. The colored spots are counted using a stereomicroscope 
or digital-imaging system.  
 
The ELISPOT assay has the following advantages: the cytokine 
released can be detected at the level of single cells, allowing for 
direct determination of cytokine-producing cell frequencies. 
This assay is more sensitive than ELISA and intracellular 
staining. The sensitivity of the assay enables measurement of 
very low frequencies of cytokine-producing cells (e.g. 
~1/300,000). Objective and rapid analyses of cytokine 
producing cell numbers (spots), and relative amounts of 
cytokine produced per cell (spot size) are now possible. Recent 
developments in assay plate design and in high-throughput 
ELISPOT plate-reader instrumentation have significantly 
improved the utility of the ELISPOT method. 
 
RESULTS AND DISCUSSION 
 
Since their development in the early 1990s, differential gene 
expression technologies have been applied to a multitude of 
biological challenges, both for the purpose of basic biological 
research and as a valuable tool for the discovery, validation 
and development of pharmaceuticals (25). 
 
We believe that chemokine detection using the techniques 
listed above will provide useful clinical information about HIV 
infection by examining the association between different 
chemokine profiles and disease progression (26). We have 
presented results of for our neuronal cell lines which have been 
treated with morphine at 10
-7 and 10
-9 M concentration. Herein 
we have shown how various techniques including, RT-PCR, 
ELISA, real-time quantitative PCR, western blot and flow 
cytometry can be used to investigate the effects of treatment of 
CNS cells with morphine. Results from all these chemokine 
detection methods demonstrates that morphine downregulates 
the expression of chemokines while simultaneously 
upregulating the expression of their receptors. Discussed below 
are the various methodologies used for chemokine analysis, 
outlining the special features of each. 
 
To identify the specific genes that are modulated by a specific 
biological process we used gene array analysis. Gene 
expression profiling provides an overview of the activation of 
many genes involved in various disease processes. However, 
the conventional microarray (gene chip), with the ability to 
examine tens of thousands of genes are now being replaced by 
a second generation of arrays that are more focused, 
application-specific and lower-cost. The gene arrays we use 
used for our study are made to our specifications by Superarray 
Inc. (Bethesda MD). They consist of a membrane with cDNA 
from about 20 different genes allowing more focused analyses 
of specific biological activities.  
 
To maintain a high level of reliability, sensitivity and 
specificity, these arrays have cDNA fragments from 300bp to 
600bp, selected by computer algorithms to minimize cross-
hybridization. Sometimes sequences outside the coding region 
are included to make the specificity unique for each gene. All 
cDNA fragments spotted on the array are indexed by Genbank 
accession numbers to allow the end-user to validate the array 
data with independent methods, such as northern blots or 
quantitative RT-PCR.  
 
We developed a semi-quantitative RT-PCR assay to analyze 
expression of the mRNA of the human chemokines , RANTES, Mahajan et al.    
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MIP-1β, MCP-1, and IL-8 as well as their respective receptors, 
CCR3, CCR5, CCR2b, and CXCR2. The assay showed a high 
sensitivity and within assay and inter-assay variability was 
below 5%. This method allows the direct, semi-quantitative 
comparison of the expression of different chemokine mRNA 
levels from relatively small cell numbers or small tissue 
specimens. Although RT-PCR is a sensitive tool for assaying 
mRNA, it is not precise due to the exponential nature of the 
amplification process. Also it is an end point analysis and thus 
provides only semi-quantitative results. Indeed, small 
variations in the amplification efficiency can result in dramatic 
changes in product yields. To overcome this difficulty, real-
time, quantitative PCR was developed. Real–time experiments 
are performed on a sequence detection instrument capable of 
detecting fluorescence from samples during each cycle of a 
PCR protocol. In real-time analysis the accumulation of the 
product is measured and reported during every cycle of the 
reaction. These measurements allow a threshold cycle (Ct) to 
be determined for each reaction. The Ct occurs when the 
sequence detection application begins to detect an increase in 
signal associated with an exponential increase in PCR product. 
The passive reference dye, ROX, does not participate in the 
amplification reaction but provides an internal reference to 
which the reporter-dye signal can be normalized during data 
analysis. Because the product is measured immediately upon 
amplification above the background, the problem of limiting 
reagent during PCR can be monitored. Normalization is 
necessary to correct for fluorescent fluctuations due to changes 
in concentration or volume. Normalization controls ensure that 
the quantitative PCR reaction is yielding similar amplification 
efficiency in each run. Housekeeping genes like G3PDH or β 
actin are used because they are abundant in most samples and 
show little variation between experiments. 
 
Quantitative real-time PCR is routinely performed in our 
laboratory since the cost and availability of the Taqman probes 
and SYBR green Q-PCR master mixes have decreased 
significantly due to competition. Quantitative PCR shows a 
high sensitivity (below 60 cDNA molecules / 10 µl reaction) 
and dynamic range (8 log units); both within assay and inter-
assay variability were below 0.06 log units and accuracy was 
±0.06 log units for all chemokines tested in our laboratory 
using the 5700 Gene Amp Sequence detection system. 
Quantitative results based on Ct are more accurate than results 
derived from end point determinations because Ct derived 
quantification is determined from measurements taken during 
the early exponential phase of PCR amplification before 
efficiency is affected by limiting reagents and product re-
annealing.  
 
Gene expression data provide an understanding of gene 
regulation in a specific biological process at the transcriptional 
level. However protein detection methods such as ELISA and 
western blots are necessary to determine whether the 
transcribed gene is ultimately translated into protein. ELISA is 
the easiest and fastest assay to precisely measure pg quantities 
of proteins. ELISA kits to facilitate the assay of chemokines in 
biological samples are commercially available. Using such 
kits, we have measured levels of various chemokines in serum 
from patients as well as supernates of cultured cells. Results 
obtained using kits from several manufacturers differed 
slightly but were well within acceptable ranges of variance. 
This variability may be due to differences in specificity and 
sensitivity of the unique monoclonal antibodies employed in 
each kit. Factors influencing variability between ELISA kits 
may include: (i) denaturation of the recognized epitope within 
the cytokine, (ii) fragmentation of the cytokine following 
enzymatic cleavage (iii) binding of cytokines to undefined 
ligands, (iv) variable glycosylation of the cytokines, and (v) 
recognition of precursor forms of cytokines which would 
interfere with their measurements. 
 
With the many different cytokine assays available, one must 
decide on which will provide the best information for the study 
being undertaken. Both the choice of chemokine assay and 
evaluation of the results are complex issues. No single method 
can answer all likely questions. Thus more than one assay may 
be necessary for optimal results. Examples derived from our 
own studies demonstrating the use of multiple assays for 
detecting gene expression by cells is provided below. The data 
presented in Figures 1, 2, 4 and 5, and Tables 2 and 3 show the 
effect of morphine treatment on chemokine and chemokine 
receptor gene expression by CNS cells. Figure 3 shows the 
effect of morphine on µ receptor expression by CNS cells as 
determined by western blot. All the data presented in Figures 1 
to 5 is representative of three separate experiments. The 
statistical method used for data analysis was analysis of 
variance between groups (ANOVA). 
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Fig. 1: Results of semiquantitative RT-PCR show that morphine inhibits MIP-1β gene expression in U373 cells. U373 cells (3 X 10
6 /ml) were cultured with 
or without morphine for 24 hr. RNA was extracted, reverse transcribed and amplified by PCR using housekeeping gene, G3PDH, and MIP-1β specific primers. 
PCR products were separated by electrophoresis on a 1.2% agarose gel. 1A: G3PDH expression remained unchanged at both morphine concentrations. 1B: 
Morphine inhibits MIP-1β gene expression at 10
-7 and 10
-9 M concentrations. 1C: Quantitation of the effect of morphine on MIP-1β gene expression by 
densitometry after nomalization with corresponding values of G3PDH expression in A; these data are the mean ± SD of 3 separate experiments. 
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Fig. 2: Effect of morphine on IL-8 protein secretion in U87 and NHA cells. IL-8 protein levels as quantitated by ELISA assay kit from Biosource Inc. The 
minimum detectibility of the assay is 0.1 pg/ml. Morphine at 10
-7 and 10
-9 M suppressed IL-8 production. 
 
Table 2: MIP-1β protein levels as quantitated by ELISA assay kit from R & D Systems, Inc. The minimum detectibility of the assay is 4 pg/ml. Morphine  at 
10
-7 and 10
-9 M suppressed MIP-1β production 
U373 MIP-1β (pg/ml) 
1. Control  1052.6 + 52.67 
2. Morphine 10
-7M 675.9  + 21.43 p<0.0001 
3. Morphine 10
-9M 727.6  + 27.59 p<0.0001 
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Fig. 3: Effect of morphine on the phenotypic expression of CCR5 on U373 cells. U373 cells were cultured with and without 10
-7 M morphine for 24 hr and 
subjected to FACS analysis. FL-1 (Fluorescence axis -1), represents the FITC labelled cells, while FL-2 (Fluorescence axis -2), represents the phycoerythrin or PE  
labelled cells. The CCR5 positive cells shown in the quandrants above are labelled with an anti CCR5 FITC- MAb. Panel 3A shows the Isotype Control used as a 
negative control to set quadrant markers. 3B: Untreated control cells showing that 0.95% of the total cells constitutively express CCR5 on their surface. 3C: 
Morphine treatment of U373 cells produces a significant increase in CCR5 positive cells to 2.98%. 3D: Representative histogram showing Mean values + SD of 
CCR5 positive cells from 3 experiments. Mahajan et al.   101 
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Fig. 4: Effect of morphine on the opioid µ receptor expression by U373, and U87. CNS cells were treated with 10
-7 M morphine for 72 hr. After incubation total 
protein was extracted and 30 µg was separated on 7.5% SDS-Tris glycine PAGE. Gels were then subjected to western blot analysis using antibodies specific for the 
opioid µ receptor. The opioid µ receptor migrates as a 45 kDa band. Fig. 4A: MW, Pre stained SDS-PAGE molecular marker standard. Fig. 4B & 4C: untreated 
control and 10
-7 M Morphine treated cells in U87 and U373 cells.  Fig. 4D: Reprepresentative histogram showing the percent increase in µ receptor expression 
between morphine treated and untreated controls in U87 and U373 cells. Treatment with morphine at 10
-7 M upregulated µ receptor expression in both U87 and 
U373 cells. 
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Fig. 5: MIP-1β gene expression levels as quantitated by Real time quantitative PCR using SYBR green master mix from (Stratagene, CA). TAI= 2
-∆∆Ct gives 
the Transcript Accumalation Index or The Relative gene expression as compared to the control. Morphine at 10
-7  and 10
-9 M downregulated MIP-1β gene 
expression. 
 
Table 3: 
U373  MIP-1β (TAI=2
-∆∆Ct ) 
1. Control  1.0 + 0.00 
2. Morphine 10
-7M 0.42  + 0.07   p<0.007 
3. Morphine 10
-9M 0.52  +  0.03 p<0.002 
 